Promis Neurosciences Inc., of Toronto, said it entered an agreement with Mackie Research Capital Corp. to offer, on a private placement basis, up to 12 million units at C25 cents per unit for proceeds of up to C$3 million ($2.38 million).

Manuel Pena, of Houston, was sentenced Wednesday in federal court to 15 months in prison, followed by two years of supervised release on his conviction of conspiracy to import prescription drugs into the U.S. from India.

HONG KONG – After a prolonged negotiation process, China has secured drug prices that are, in some cases, much lower than those in Europe and other developed markets.

Oryzon Genomics SA is losing its only partner, for lead candidate ORY-1001 (RG-6016), after Roche Holding AG reprioritized its pipeline and abandoned development of the lysine specific demethylase-1 (LSD1) inhibitor.

Trevi Therapeutics Inc. said a new $50.5 million series C financing led by New Enterprise Associates will help it advance the development of Nalbuphine ER, a twice-daily oral opioid in development for the treatment of two forms of severe itching. The round included new investors Lundbeckfonden Ventures, Omega Funds and Aperture Venture Partners, along with TPG Biotech, Trevi's largest investor and the leader of its $12.8 million series A in December 2012 and $25 million series B round in June 2014.

LONDON – Worldwide progress in treating HIV infection is threatened by a rising trend of resistance to antiretroviral drugs, according to the 2017 World Health Organization (WHO) HIV Drug Resistance report, due to be launched at the International AIDS Society conference in Paris on Sunday.

As the company made its second acquisition in a month, Emergent Biosolutions Inc. CEO Daniel Abdun-Nabi vowed that the hunt for more prospects will continue and could include "vaccines, therapeutics, devices across the chemical, biological, radiological, nuclear and explosives [or CBRNE federal countermeasures spectrum], as well as emerging infectious disease spaces. They could be products. They could be full businesses. The whole portfolio of opportunities that we're looking at is quite broad."

Theravance Biopharma Inc., of Dublin, and Mylan NV, of Hertfordshire, U.K., reported results from a 12-month phase III safety study of revefenacin (TD-4208), a long-acting muscarinic antagonist and a proposed once-daily, nebulized bronchodilator in development for the treatment of chronic obstructive pulmonary disease (COPD).

DUBLIN – The EU's transparency watchdog, the EU Ombudsman, has questioned whether the EMA has an overly cosy relationship with industry.

U.S. congressional appropriators continue to march to a different drumbeat than the cadence President Donald Trump directed for the NIH and FDA.